These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 7636541)

  • 1. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
    Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA
    J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
    Cullen MH; Stuart NS; Woodroffe C; Murphy A; Fletcher J; Blackledge GR; Child JA; Grieve RJ; Jones EL
    J Clin Oncol; 1994 Apr; 12(4):779-87. PubMed ID: 7512132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
    Brusamolino E; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Bernasconi P; Astori C; Lazzarino M
    Ann Oncol; 1994 May; 5(5):427-32. PubMed ID: 7521204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
    Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
    J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
    Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
    J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE; Hoskins P; Klimo P; Connors JM
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.
    Radford JA; Crowther D; Rohatiner AZ; Ryder WD; Gupta RK; Oza A; Deakin DP; Arnott S; Wilkinson PM; James RD
    J Clin Oncol; 1995 Sep; 13(9):2379-85. PubMed ID: 7666097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.